HER2+ Early Breast Cancer: Who Can Safely Receive Less?
HER2+ Early Breast Cancer: Who Can Safely Receive Less? Medscape
411 материалов по теме, собраны автоматически из проверенных источников
HER2+ Early Breast Cancer: Who Can Safely Receive Less? Medscape
Breast Cancer Is the Leading Cause of Cancer Death Among Latinas, and for Many, Treatment Doesn't End When the World Thinks It Does https://fiercebymitu.com/
Session 1: Estrogen Receptor Biomarker Testing, Targeting Mechanisms, and Treatment Decisions in Breast Cancer Care HMP Global Learning Network
Session 2: From ESR1 Testing to Treatment Selection: Understanding ER-Targeted Approaches in Breast Cancer HMP Global Learning Network
Ablation Falls Short in Oligometastatic Breast Cancer Trial Medscape
How Breast Cancer Cells Cope With Stress Points to Potential Drug Target Technology Networks
В больницу № 5 Уфы поступил новый маммограф ГТРК «Башкортостан
Endeavor joins breast cancer research consortium, adding suburban reach Crain's Chicago Business
JMIR Cancer Opens Call for Breast Cancer Research to Mark Awareness Month Bioengineer.org
FDA Approves Tukysa Maintenance Treatment for HER2-Positive Metastatic Breast Cancer WebMD
Endeavor Health joins Chicago Breast Cancer Research Consortium Evanston RoundTable
A new study in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, while ABUS had a lower false-positive rate. The study demonstrates that ABUS is a viable alternative to HHUS…
Finding meaning in my stage 3 triple-negative breast cancer diagnosis UT MD Anderson
JMIR Publications’ JMIR Cancer invites submissions on breast cancer EurekAlert! Science News Releases
Pfizer Tukysa Regimen Gets FDA Nod for Maintenance Treatment of HER2+ Metastatic Breast Cancer Contract Pharma